MedPath

Omrix Biopharmaceuticals

🇧🇪Belgium
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:2

Drug Approvals

4

CIMA_AEMPS:4

Drug Approvals

EVICEL SOLUCIONES PARA ADHESIVO TISULAR

Approval Date
Jul 14, 2025
CIMA_AEMPS

EVARREST MATRIZ ADHESIVA

Approval Date
Jul 14, 2025
CIMA_AEMPS

EVICEL SOLUCIONES PARA ADHESIVO TISULAR

Approval Date
Jul 14, 2025
CIMA_AEMPS

EVICEL SOLUCIONES PARA ADHESIVO TISULAR

Approval Date
Jul 14, 2025
CIMA_AEMPS

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 3
2 (50.0%)
Phase 1
1 (25.0%)
Phase 2
1 (25.0%)

Evaluation of Adhexil Safety and Efficacy in Prevention and/or Reduction of Adhesions in Gynecological Surgery

Phase 3
Suspended
Conditions
Ovarian Cysts
Endometriosis
Adhesions
First Posted Date
2009-03-19
Last Posted Date
2009-12-23
Lead Sponsor
OMRIX Biopharmaceuticals
Target Recruit Count
80
Registration Number
NCT00865488

Safety and Hemostatic Efficacy of Fibrin Fleece in Partial Nephrectomy

Phase 2
Completed
Conditions
Hemostatic Techniques
Nephrectomy
First Posted Date
2008-01-18
Last Posted Date
2009-11-06
Lead Sponsor
OMRIX Biopharmaceuticals
Target Recruit Count
30
Registration Number
NCT00598130
Locations
🇮🇱

Bnei-Zion MC, Haifa, Israel

🇮🇱

Meir MC, Kfar Saba, Israel

🇮🇱

Rabin MC, Tel Aviv, Israel

and more 1 locations

Pilot Study Evaluating the Safety and Potential Trends in Efficacy of Adhexil

Phase 1
Conditions
Bilateral Ovarian Disease
First Posted Date
2007-10-16
Last Posted Date
2008-08-20
Lead Sponsor
OMRIX Biopharmaceuticals
Target Recruit Count
25
Registration Number
NCT00544310

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.